Cellectar Biosciences, Inc.CLRBNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank56
5Y CAGR-10.8%
Year-over-Year Change
Year-over-year SG&A expense growth
5Y CAGR
-10.8%/yr
Long-term compound
Percentile
P56
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 9.12% |
| Q3 2025 | -37.63% |
| Q2 2025 | 22.66% |
| Q1 2025 | -54.50% |
| Q4 2024 | -16.58% |
| Q3 2024 | 23.21% |
| Q2 2024 | 29.40% |
| Q1 2024 | 6.55% |
| Q4 2023 | 93.85% |
| Q3 2023 | 10.18% |
| Q2 2023 | -7.97% |
| Q1 2023 | 19.16% |
| Q4 2022 | -19.16% |
| Q3 2022 | -17.08% |
| Q2 2022 | 30.34% |
| Q1 2022 | 46.77% |
| Q4 2021 | -18.43% |
| Q3 2021 | 34.34% |
| Q2 2021 | -18.84% |
| Q1 2021 | 21.19% |
| Q4 2020 | 16.19% |
| Q3 2020 | 5.98% |
| Q2 2020 | -13.82% |
| Q1 2020 | 10.91% |
| Q4 2019 | -3.95% |
| Q3 2019 | -9.40% |
| Q2 2019 | 5.25% |
| Q1 2019 | 12.69% |
| Q4 2018 | 7.39% |
| Q3 2018 | -7.61% |
| Q2 2018 | -11.10% |
| Q1 2018 | 34.47% |
| Q4 2017 | -14.08% |
| Q3 2017 | 10.59% |
| Q2 2017 | 8.92% |
| Q1 2017 | -20.92% |
| Q4 2016 | 3.94% |
| Q3 2016 | -15.02% |
| Q2 2016 | 42.29% |
| Q1 2016 | 20.25% |